|
Published by: Freedonia Group Inc
Published: Nov. 1, 2002 - 331 Pages
Table of Contents Introduction
I. Executive Summary
II. Market Environment
- General
- Economic Factors
- Recent Economic Trends
- Long-Term Economic Projections
- Demographic Patterns
- Trends in Health Care
- Medical Conditions
- Acute Conditions
- Chronic Conditions
- National Health Expenditures
- Hospital Care & Physicians’ Services
- Medical Nondurable Goods
- Nursing Home Care
- Other Personal Health Expenditures
- Non-Personal Health Expenditures
- Patient Activity
- Hospital Activity
- Surgical Procedures
- Outpatient & Home Health Care Episodes
- Retail Prescriptions
- Diagnostic Tests
- Trends in Consumable Medical Products
- Regulation
- Research & Development
- Product Demand Patterns
- Pharmaceuticals
- Diagnostic Substances
- Human Use Biologicals
- Research Consumables
- Agricultural, Environmental & Industrial Markets
- US Trade
- International Markets
III. Product Overview
- General
- Conventional Biologics
- Recombinant Proteins
- Monoclonal Antibodies
IV. Conventional Biologics
- General
- Blood & Blood Derivatives
- Cellular Components
- Packed Red Blood Cells
- Platelets
- Stem Cells
- Plasma Fractions
- Human Serum Albumin
- Immune Globulins
- Other Plasma Products
- Whole Blood
- Blood Substitutes
- Conventional Protein Drugs
- Anticoagulants
- Hormones
- Antineoplastic Agents
- Enzymes
- Other Conventional Proteins
- Conventional Vaccines
- Pneumococcal Vaccines
- Diphtheria, Tetanus & Acellular Pertussis (DTaP) Vaccines
- Measles-Mumps-Rubella (M-M-R) Vaccines
- Influenza Vaccines
- Hepatitis A Vaccines
- Varicella (Chickenpox) Vaccine
- Cancer Vaccines
- AIDS Vaccines
- Other Conventional Vaccines
- Veterinary Vaccines
- Livestock & Poultry Vaccines
- Companion Animal Vaccines
- Other Conventional Biologics
- Diagnostic Reagents
- Enzymes
- Hormones
- Antigens & Antibodies
- Hematology Reagents
- Research Reagents
- All Other Conventional Biologics
V. Recombinant Proteins
- General
- Demand Patterns
- Blood-Related Agents
- Erythropoietins
- Epoetin Alfa
- Darbepoetin Alfa
- Colony Stimulating Factors
- Filgrastim & Pegfilgrastim
- Sargramostim
- Antihemophilic Blood Factors
- Antihemophilic Factor VIII
- Antihemophilic Factor IX
- Other Antihemophilic Factors
- Thrombolytic Agents
- Tissue Plasminogen Activators
- Direct Thrombin Inhibitors
- Recombinant Hormones
- Human Insulin
- Regular Human Insulin
- Human Insulin Analogs
- Human Growth Hormones
- Other Recombinant Hormones
- Fertility Hormones
- All Other Hormones
- Interferons
- Beta Interferons
- Alfa Interferons
- Other Interferons
- Recombinant Vaccines
- Hepatitis B Vaccines
- Other Recombinant Vaccines
- Other Recombinant Proteins
- Biological Response Modifiers
- Enzymes
- All Other Recombinant Proteins
VI. Monoclonal Antibodies
- General
- Diagnostic & Research Monoclonal Antibodies
- In Vitro Diagnostic Reagents
- Immunological Reagents
- Hematology & Related Reagents
- Research Reagents
- In Vivo Diagnostic Agents
- Therapeutic Monoclonal Antibodies
- Anti-Cancer Agents
- Anti-Inflammatory Agents
- Other Therapeutic Monoclonal Antibodies
- Thrombolytic Agents
- Anti-Transplant Rejection Agents
- All Other Therapeutic Monoclonal Antibodies
VII. Raw Materials
- General
- Active Biologic Ingredients
- Conventional Biologics
- Recombinant Proteins
- Monoclonal Antibodies
- Capacity
- Contract Manufacturing Services
- Industry Trends
VIII. Applications
- General
- Human Health Care
- Infectious & Viral Diseases
- Cancer
- Cardiovascular Diseases
- Other Human Health Care
- Animal Health Care
- Other Applications
IX. Markets
- General
- Health Care Markets
- Ambulatory Health Care
- Pharmacies
- Hospitals
- Other Health Care Markets
- Veterinarians & Livestock Breeders
- Industrial Markets
- Other Biologic Markets
X. Industry Structure
- General
- Competitive Trends
- Market Share
- Competitive Strategies
- Mergers & Acquisitions
- Licensing & Related Agreements
- Research & Development
- Manufacturing
- Marketing & Distribution
- Company Profiles
- Abbott Laboratories
- Abgenix Incorporated
- Acambis plc
- Akzo Nobel NV
- American Home Products Corporation, see Wyeth
- Amgen Incorporated
- Avecia Group plc
- Aventis SA
- Aviron, see MedImmune Incorporated
- Bard BioPharma, see Laureate Pharma LP
- Baxter International Incorporated
- Bayer AG
- Ben Venue Laboratories Incorporated, see Boehringer Ingelheim GmbH
- Berlex Laboratories Incorporated, see Schering AG
- Bio Science Contract Production Corporation, see Cambrex Corporation
- Biogen Incorporated
- BioMarin/Genzyme LLC, see Genzyme Corporation
- Biopure Corporation
- BioWhittaker Incorporated, see Cambrex Corporation
- Boehringer Ingelheim GmbH
- Cambrex Corporation
- Centocor Incorporated, see Johnson & Johnson
- Chiron Corporation
- Covance Biotechnology Services Incorporated, see Akzo Nobel NV
- Covance Incorporated
- Daiichi Pharmaceutical Company Limited
- Degussa AG
- Diosynth, see Akzo Nobel NV
- Dow Chemical Company
- DSM NV
- EPIcyte Pharmaceutical Incorporated
- Fort Dodge Animal Health, see Wyeth
- Fusion Medical Technologies Incorporated, see Baxter International Incorporated
- Genencor International Incorporated
- Genentech Incorporated
- Genzyme Corporation
- GlaxoSmithKline plc
- Hesed Biomed Incorporated, see Abgenix Incorporated
- Hoffmann-La Roche Incorporated, see Roche Holding Limited
- IDEC Pharmaceuticals Corporation
- Immunex Corporation, see Amgen Incorporated
- Intervet, see Akzo Nobel NV
- Invitrogen Corporation
- Jeffreys (George A.) Incorporated, see Novozymes A/S
- Johnson & Johnson
- Kirin Brewery Company Limited
- Knoll GmbH, see Abbott Laboratories
- Laureate Pharma LP
- Life Technologies Incorporated, see Invitrogen Corporation
- Lilly (Eli) and Company
- Lonza Group Limited
- Marathon Biopharmaceuticals, see Cambrex Corporation
- MedImmune Incorporated
- Merck & Company Incorporated
- Nabi Biopharmaceuticals
- Novartis International AG
- Novazyme Pharmaceuticals Incorporated, see Genzyme Corporation
- Novo Nordisk A/S
- Novozymes A/S
- OraVax Incorporated, see Acambis plc
- Organon International, see Akzo Nobel NV
- Ortho-Clinical Diagnostics Incorporated, see Johnson & Johnson
- Peptide Therapeutics Group plc, see Acambis plc
- Pfizer Incorporated
- Pharmacia Corporation
- Proligo LLC, see Degussa AG
- Protein Design Labs Incorporated
- Roche Holding Limited
- Schering AG
- Schering-Plough Corporation
- Serono SA
- SmithKline Beecham plc, see GlaxoSmithKline plc
- Sybron Biochemicals, see Novozymes A/S
- Wyeth
AbstractUS demand for biologics will
advance almost 12 percent
annually to over $56 billion in
2006. New product introductions evolving from advances
in recombinant DNA and
monoclonal antibodies will
spur growth. Applications in
the treatment, prevention and
diagnosis of complex viral,
malignant and auto-immune
disorders will see the strongest gains in demand due to
the safety and performance
shortcomings of available
conventional products.
Details on these and other key
findings are provided in Biologics. This US
study provides historical data
through 2001 plus forecasts to
2006 and 2011 for biologic
products by type, application
and end-use market. Opportunities for fine chemical
companies in the supply and
contract production of
biologic materials are also
analyzed. In addition, the
study assesses the competitive
structure of the US biologics
industry, and includes profiles
of major companies participating in the field.
Please Note: Freedonia requires that, for PDF orders, clients sign a confidentiality agreement prior to fulfillment of PDF email delivery.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.
© MarketResearch.com 2008
|